Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.71 USD

8.71
2,081,596

+0.09 (1.04%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

by Zacks Equity Research

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

by Zacks Equity Research

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

Foamix Initiates Phase II Study on Acne Combination Foam

by Zacks Equity Research

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

by Zacks Equity Research

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

by Zacks Equity Research

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?

Is Bausch Health Cos (BHC) a Good Value Investor Pick?

by Zacks Equity Research

Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

by Zacks Equity Research

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

Bausch Health (BHC) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of -2.83% and -0.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

by Zacks Equity Research

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Aerie Completes Enrollment Under Rhopressa Study in Japan

by Zacks Equity Research

Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

by Zacks Equity Research

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

Indrajit Bandyopadhyay headshot

Price Stabilization Leads to Generic Drugs Industry's Recovery

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.

Dova Receives Approval for Doptelet in Europe, Stock Up

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

by Zacks Equity Research

Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Allergan Up As Analyst Statement Sparks Business Split Rumors

by Zacks Equity Research

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?